Methylphenidate for attention-deficit/hyperactivity disorder in patients with Smith–Magenis syndrome: protocol for a series of N-of-1 trials

Methylphenidate for attention-deficit/hyperactivity disorder in patients with Smith–Magenis syndrome: protocol for a series of N-of-1 trials

Abstract Background Smith–Magenis syndrome (SMS) is a rare genetic neurodevelopmental disorder characterized by intellectual disability and severe behavioural and sleep disturbances. Often, patients with SMS are diagnosed with attention-deficit/hyperactivity disorder (ADHD). However, the effectivene...

Full description

Bibliographic Details
Main Authors: A. R. Müller, J. R. Zinkstok, N. N. J. Rommelse, P. M. van de Ven, K. C. B. Roes, F. A. Wijburg, E. de Rooij-Askes, C. Linders, E. Boot, A. M. van Eeghen
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Orphanet Journal of Rare Diseases
Subjects:
N-of-1
Smith–Magenis syndrome
Methylphenidate
Rare genetic neurodevelopmental disorder
Multiple crossover
ADHD
Online Access:https://doi.org/10.1186/s13023-021-02003-z

Internet

https://doi.org/10.1186/s13023-021-02003-z

Similar Items